FDA Approves Ozurdex for Treatment of Uveitis Affecting Posterior Segment of Eye
September 28, 2010
Submit Comments
In late September, Allergan announced that announced that the FDA had approved OZURDEX(R) (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye. Posterior uveitis is the cause of 10 to 15 percent of cases of blindness in the United States.
OZURDEX(R) is a biodegradable implant that delivers an extended release of the corticosteroid dexamethasone via intravitreal injection with Allergan’s proprietary and innovative NOVADUR(R) solid polymer delivery system.
Read Allergan’s full press release here.
You might also enjoy...
- Allergan Announces FDA Approval for OZURDEX™ For Treatment of Macular Edema Following Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion
- Can Steroid Implant Treat Noninfectious or Posterior Uveitis?
- Are Time-Release Implants an Effective Treatment for Uveitis?
- Is Iluvien From Alimera Sciences the Future of Ophthalmic Drug Delivery?
- pSivida’s Injectable Sustained-Release Micro-Insert for Treatment of Uveitis Proceeding to Phase III Trials
Comments
Jump down to form below to submit your own comments
